Abstract
2037 Background: For ovarian cancer patients, it remains unclear whether carboplatin should be administered intraperitoneally (IP) or intravenously (IV). Because it is virtually impossible to measure the actual tissue concentration in peripheral organs, we have developed a three-compartment mathematical model for both IP and IV administration to estimate the pharmacological information in the serum (S), [the] peritoneal cavity (CV), and [the] peripheral space (PRH) Methods: Twenty two patients with ovarian cancer were enrolled in this study; two groups of 11 patients each received carboplatin IP or IV, respectively. Carboplatin (AUC 6) was diluted in 500 ml 5% glucose and administered either as an IP bolus infusion or IV drip infusion in 1 hr. Patients receiving IV injections also received an infusion of 500 ml 5% glucose to enable us to obtain intraperitoneal samples. IP fluid and blood samples were obtained, immediately, 1, 2, 4, 8, 12 and 24 hrs after administration. The free platinum was measured by a...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
